



Field study on the use of vaccination to control the occurrence of lumpy skin disease in Ethiopian cattle

Molla, W., Frankena, K., Gari, G., & de Jong, M. C. M.

This is a "Post-Print" accepted manuscript, which has been published in "Preventive Veterinary Medicine"

This version is distributed under a non-commercial no derivatives Creative Commons



([CC-BY-NC-ND](https://creativecommons.org/licenses/by-nc-nd/4.0/)) user license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and not used for commercial purposes. Further, the restriction applies that if you remix, transform, or build upon the material, you may not distribute the modified material.

Please cite this publication as follows:

Molla, W., Frankena, K., Gari, G., & de Jong, M. C. M. (2017). Field study on the use of vaccination to control the occurrence of lumpy skin disease in Ethiopian cattle. *Preventive Veterinary Medicine*, 147, 34-41. DOI: 10.1016/j.prevetmed.2017.08.019

You can download the published version at:

<https://doi.org/10.1016/j.prevetmed.2017.08.019>

**Field study on the use of vaccination to control the occurrence of lumpy skin disease in  
Ethiopian cattle**

Wassie Molla<sup>a,b,1</sup>, Klaas Frankena<sup>a</sup>, Getachew Gari<sup>c</sup>, Mart C.M. de Jong<sup>a</sup>

<sup>a</sup> Quantitative Veterinary Epidemiology, Wageningen University & Research,  
Droevendaalsesteeg 1, 6708 PB Wageningen, The Netherlands

<sup>b</sup> Faculty of Veterinary Medicine, University of Gondar, P.O. Box 196, Gondar, Ethiopia

<sup>c</sup> National Animal Health Diagnostic and Investigation Centre (NAHDIC), Sebeta, Ethiopia

<sup>1</sup>Corresponding author: Tel: +31613169516

E-mail address: wassie.abebe@wur.nl / mollarwassie@yahoo.com

## 1 **Abstract**

2 The current study was carried out in central and North-western parts of Ethiopia to assess the  
3 efficacy of Kenyan sheep pox virus strain vaccine (KS1 O-180) against natural lumpy skin  
4 disease (LSD) infection under field conditions by estimating its effect on the transmission and  
5 severity of the disease. For this study, an LSD outbreak was defined as the occurrence of at least  
6 one LSD case in a specified geographical area. An observational study was conducted on a total  
7 of 2053 (1304 vaccinated and 749 unvaccinated) cattle in 339 infected herds located in 10 sub-  
8 kebeles and a questionnaire survey was administered to 224 herd owners. Over 60% of the herd  
9 owners reported that the vaccine has a low to very low effect in protecting animals against  
10 clinical LSD; almost all of them indicated that the vaccine did not induce any adverse reactions.  
11 In the unvaccinated group of animals 31.1% were diagnosed with LSD while this was 22.5%  
12 in the vaccinated group ( $P < 0.001$ ). Severity of the disease was significantly reduced in  
13 vaccinated compared to unvaccinated animals (OR = 0.68, 95% CI: 0.49; 0.96). Unvaccinated  
14 infected animals were more likely (predicted fraction=0.89) to develop moderate and severe  
15 disease than vaccinated infected animals (predicted fraction=0.84).

16 LSD vaccine efficacy for susceptibility was estimated to be 0.46 (i.e. a susceptibility effect of  
17 0.54) while the infectiousness effect of the vaccine was 1.83. In other words, the vaccine  
18 reduces the susceptibility by a factor of two and increases infectiousness by approximately the  
19 same amount. LSD transmission occurred in both vaccinated and unvaccinated animals, the  
20 estimated reproduction ratio (R) was 1.21 in unvaccinated animals compared to 1.19 in  
21 vaccinated ones, and not significantly different. In conclusion, KS1 O-180 vaccination, as  
22 applied currently in Ethiopia, has poor efficacy in protecting cattle populations against LSD,  
23 neither by direct clinical protection nor by reducing transmission, and this signifies the urgent  
24 need to either improve the quality of the vaccine or to develop potent alternative vaccines that  
25 will confer good protection against LSD.

26 **Key words:** *Capripoxvirus*, Kenyan sheep pox (KS1 O-180) vaccine, Lumpy skin disease,  
27 Reproduction ratio, Severity, Vaccine efficacy

28

## 29 **1. Introduction**

30 Lumpy skin disease (LSD) is a disease of cattle caused by LSD virus, a DNA virus, which  
31 belongs to the family *Poxviridea*, subfamily *Chordopoxvirinae* and it is of the genus  
32 *Capripoxvirus*. The disease is characterized by fever, nodular lesions on the skin and mucous  
33 membranes, inflammatory and oedematous swellings of the limbs and brisket,  
34 lymphadenopathy, deterioration of body condition and drop in milk production (Davies, 1991;  
35 Quinn et al., 2002; Radostits et al., 2007). It has spread to most African countries, Middle East  
36 countries and recently to Europe (Davies, 1991; Tuppurainen and Oura, 2012; Tasioudi et al.,  
37 2016; WAHID, 2016; Tuppurainen et al., 2017). LSD is endemic in Ethiopia and is a constant  
38 threat to the livestock sector since its first occurrence in 1981 (Mebratu et al., 1984; Gari et al.,  
39 2010). LSD outbreaks occur frequently in various regional states of the country, despite  
40 intensive vaccination campaigns (APHRD, 2012). It is an economically devastating and  
41 therefore a notifiable disease as per OIE disease categorization (Gari et al., 2011; Tuppurainen  
42 and Oura, 2012; OIE, 2016).

43 Vaccination, movement control and slaughter of infected and in-contact animals are  
44 considered as options for the control of LSD. However, it is widely agreed that vaccination is  
45 the most manageable and realistic approach to control the disease in endemic and resource poor  
46 countries (Carn, 1993; Tuppurainen et al., 2014). Live attenuated vaccines based on sheep pox  
47 virus (for example, Kenyan sheep pox (KS1 O-180), Romanian sheep pox and Yugoslavian  
48 RM 65 sheep pox vaccines), goat pox virus (Gorgan goat pox vaccine), and LSDV (Neethling  
49 strain vaccine) have been used for the control of LSD (OIE, 2010; Tuppurainen et al., 2014;  
50 Gari et al., 2015).

51 In general vaccination can exert important effects, both at the individual and at the  
52 population level. It may help to directly protect vaccinated animals, reduce severity of the  
53 disease by reducing all or some of its symptoms or it may reduce transmission of pathogens by

54 lowering susceptibility and/or infectiousness, and thus also indirectly reduce the risk for other  
55 vaccinated and unvaccinated individuals to become infected (De Jong, 1994; Halloran et al.,  
56 1997; Van der Goot et al., 2007; Aznar et al., 2011; OIE, 2015). The effect of vaccine  
57 intervention on the dynamics of infectious diseases, i.e. in the population, can be estimated by  
58 the reproduction ratio (R) which is the average number of secondary cases arising from one  
59 typically infected animal during its entire infectious period (Diekmann et al., 1990; Heffernan  
60 et al., 2005).

61 LSD vaccine failure has been reported in several countries including Ethiopia. During  
62 the 2006 outbreak in Israel, 11% (4.2% in dairy and 33.7% in feedlot cattle) of RM65 (Ramayer  
63 strain) vaccinated cattle became infected (Brenner et al., 2009). In Jordan, Abutarbush (2014)  
64 reported an overall LSD morbidity of 4.7% in cattle populations vaccinated with RM65  
65 (Jovivac®) and LSD vaccine of unknown origin. Kumar (2011) reported a continued LSD  
66 outbreak in Oman for more than three months after vaccination of cattle herds with Kenyan  
67 sheep and goat pox vaccine. In Ethiopia, LSD vaccine failure has been reported since 1993  
68 (Carn, 1993). Ayelet et al. (2013) estimated morbidity to be 23.8% in the cattle population of  
69 central Ethiopia after vaccination with KS1 O-180 virus strain vaccine. However, a better  
70 protection was claimed with Neethling vaccine (1.11% morbidity) and with a 10 times higher  
71 dose of the RM65 vaccine (1.85% morbidity) (Ben-Gera et al., 2015). Vaccines in general may  
72 give only partial protection (leaky vaccines) or protect only some of the individuals (all-or-  
73 nothing) (Smith et al., 1984). In addition, further immunization failure may arise due to  
74 insufficient vaccine coverage or factors related to the host, vaccine, or vaccination quality due  
75 to handling, reconstitution or administration of the vaccine (Quinn et al., 1999).

76 Ayelet et al. (2013) and Gari et al. (2015) reported that KS1 O-180 vaccine provides  
77 incomplete protection in immunized animals. However, the level of protection and its effect on  
78 the severity of the disease have not been documented well under field conditions. KS1 O-180

79 vaccine is still applied as the sole means of LSD control in Ethiopia. Hence, the aims of this  
80 study was to assess the efficacy of KS1 O-180 virus strain vaccine against natural LSD  
81 infections under field conditions by estimating its effect on the transmission and severity of the  
82 disease.

83

## 84 **2. Materials and Methods**

### 85 **2.1. Study and study area**

86 The study consisted of two parts:

87 (1) A questionnaire survey focusing on herd owners' information regarding several aspects  
88 of vaccination which was undertaken in central and North-western parts of Ethiopia  
89 (Figure 1). In central Ethiopia, it was undertaken in Ada'a, Sebeta Hawas, Ambo, Dendi,  
90 Debrelibanos, Kuyu and Hidabu Abote districts in Oromia National Regional State. In  
91 North-western part, the data were collected from Dejen, Gozamen, Hulet Ejju Enessie  
92 and Jabitenan districts in Amhara National Regional State. The dominant agricultural  
93 production system in the study areas was mixed crop-livestock system. The grazing  
94 practice in almost all study areas was open grazing on communal pasture land where  
95 animals from a village were herded together.

96 (2) A vaccine efficacy follow-up study under field conditions was undertaken in the North-  
97 western part of Ethiopia in Mota town and the surrounding four rural kebeles (the lowest  
98 administrative structure in Ethiopia, in which at least 500 households (3,500 to 4,000  
99 persons) live and cover on average about 53 km<sup>2</sup> and 3 km<sup>2</sup> land area in rural and urban  
100 places, respectively) of Hulet Ejju Enessie district, East Gojjam Administrative Zone,  
101 Amhara National Regional State (Figure 2). The rural kebeles were Hibre Selam, Debre  
102 Gubae, Beza Bizuhan, and Ayen Berhan. Cattle populations of ten sub-kebeles were

103 enrolled in the study namely Mota (from Mota town), Akobe, Semo, and Shewaber from  
104 Hibre Selam, Atetanat and Yerez from Beza Bizuhan, Webmariam from Ayen Berhan,  
105 and Kesmender, Komma and Zenabach from Debre Gubae kebele.

## 106 **2.2. Questionnaire survey**

107 The study population for the questionnaire survey was about 13,200 cattle herd owners living  
108 in 33 selected kebeles of 11 districts. These owners were smallholder farmers with the main  
109 purpose of subsistence farming, that is: draft power for crop production, milk for consumption,  
110 manure for soil fertility and fuel, and cash income. Animals were kept in an extensive  
111 management system and most of the herds were composed of local Zebu breed cattle. Animals  
112 in this system share communal grazing and watering resources. The term “herd” in this study  
113 designates an aggregate of animals kept together day and night and owned by a household.

114

### 115 **2.2.1. Study design and data collection**

116 Eleven districts located in the central and north-western parts of Ethiopia were identified for a  
117 cross-sectional questionnaire survey. The districts were selected based on the recent LSD  
118 outbreak occurrence, location and accessibility. For this study, an LSD outbreak was  
119 considered, if at least one case of LSD occurred in a specified geographical area (usually  
120 kebele). Three kebeles were randomly selected from each district. From each kebele, five to  
121 eight herd owners willing to participate were interviewed. The survey data were collected from  
122 a total of 224 herd owners from January 2015 to May 2015.

123 The data were collected by face to face interview using the local language. After getting an  
124 informed consent from the herd owners, the interviewer asked questions about the vaccination  
125 status, vaccination frequency, the vaccination service provider, fee of the vaccination, the  
126 vaccination date and when the animals become infected if there was any infected animal in his  
127 herd. Furthermore, the herd owners were requested to express their opinion on the effectiveness



128 of the vaccine in protecting cattle against LSD and the adverse reactions to the vaccine. The  
129 vaccine is considered to be protective from day 21 to one year post vaccination. All responses  
130 were recorded in a predesigned response sheet.

131

### 132 2.2.2. Data management and analysis

133 Descriptive statistics were used to summarise the data on vaccination coverage at herd level,  
134 frequency of vaccination, and owner's opinion about the effectiveness and adverse reactions of  
135 the LSD vaccine.

136

### 137 **2.3. Follow-up study**

138 A follow-up study was carried out after the index case of LSD appeared in Beza Bizuhan kebele  
139 at the specific village called Chech on 29 April 2014. The disease stayed restricted in the village  
140 for a reasonable period of time but after that it spread to other villages and surrounding kebeles.  
141 The selected area for follow-up was Mota town and its surrounding area, representing 10 sub-  
142 kebeles. In the area, animals were owned by smallholder farmers with the main purpose of  
143 subsistence farming except for six dairy farms which kept cattle for commercial purposes. Most  
144 of the herds were composed of local Zebu breed cattle and managed under extensive  
145 management. The six dairy herds consisted mainly of Holstein-Zebu cross and were managed  
146 under semi-intensive or intensive conditions.

147 The study population included 7464 heads of cattle grouped in 1203 herds. The cattle  
148 population in each sub-kebele (considered as ten separate populations as they were herded on  
149 common pasture land within a sub-kebele) was vaccinated partially. This partial coverage was  
150 not purposive but due to the failure of the owner to get their animals vaccinated. The vaccination  
151 campaign was undertaken at least one month before the entrance of the disease into a specific

152 sub-kebele. The vaccination was provided by the public veterinary service of the Hulet Ejju  
153 Enessie district following the index case appearance in the area.

154

#### 155 2.3.1. Study design and herd selection

156 This study was designed as a prospective cohort study. At the beginning of the study, ten cattle  
157 populations (i.e. all cattle in a sub-kebele excluding calves less than 6 month old) with partial  
158 vaccination coverage and LSD free status were selected. All herds in the selected populations  
159 were inspected on a weekly basis for clinical signs of LSD. The herd owners were also asked  
160 to report any suspicion of the disease. The sub-kebeles were selected based on their partial  
161 vaccination status. We selected populations with different vaccination coverage because that is  
162 a pre-requisite to estimate both vaccine efficacy for susceptibility and infectiousness (Longini  
163 et al., 1998; Aznar et al., 2011). The vaccination coverage level in the selected 10 sub-kebele  
164 cattle populations ranged from 3-95%. Since the vaccine coverage was strictly inferior to 100%,  
165 a number of infections within the vaccinated group was expected to occur. The animals, whether  
166 vaccinated or not, were followed starting from August 1, 2014 to November 31, 2014, i.e. from  
167 the day the first case was detected in the sub-kebele until no more new cases were recorded. If  
168 an animal in a herd was diagnosed with LSD and the owner volunteered to participate, the herd  
169 was enrolled in the study. Therefore, the main inclusion criteria for a herd were the infection  
170 status of the herd and the willingness of the owner to participate. A herd was considered positive  
171 if at least one animal showed LSD-characteristic nodular lesions. In total, 448 herds were  
172 recorded as being affected and of these, 339 farmers (75.7%) were willing to participate and all  
173 their bovines (n=2053) enrolled in the study.

174

#### 175 2.3.2. Data collection

176 In the ten sub-kebeles, infected herds were visited twice a week by animal health professionals  
177 and by the first author, and clinical signs were recorded. The severity of LSD was assessed at  
178 three levels: mild, moderate and severe. Mild LSD was defined as only few nodular lesions (<5)  
179 in some part of the body, mild fever (39-39.5<sup>0</sup>C) and quick recovery (within a week); the  
180 moderate level was assigned if fever, inappetence, many nodular lesions/swelling on the limb  
181 or brisket, and weakness was present; severe LSD was scored if high fever (>40<sup>0</sup>C), extensive  
182 nodular lesions/swellings, anorexia, weakness, emaciation or death was observed.

183 Animal data including breed, sex, age and records like vaccination status, vaccination  
184 date and type of vaccine used were compiled for all animals at the first herd visit. Type of herd  
185 and sub-kebele were also recorded. The first visit was made by the district veterinary team and  
186 the first author. The animal health professionals who collected the data from infected animals  
187 were blind for the vaccination status of the affected animals.

188 Biopsy samples of skin nodules were collected from a sample of the affected animals in  
189 each sub-kebele and analysed by conventional and Snapback Real-time PCR (polymerase chain  
190 reaction) techniques following the method described by Tuppurainen et al. (2005) and Gelaye  
191 et al. (2013) to confirm that the clinically observed disease truly was LSD. A total of 34 skin  
192 samples were collected for LSD confirmation.

193

### 194 2.3.3. Vaccine used for control and prevention of LSD

195 The live attenuated vaccine of KS1-O180 produced by National Veterinary Institute (NVI),  
196 Ethiopia was the only vaccine used for prevention and control of LSD in Ethiopia. It recently  
197 has been reported that the virus used for the production of KS1-O180 is not a sheep pox virus  
198 but was found to be LSDV (Gelaye et al., 2015). The vaccine was prepared in 20 ml vials  
199 containing 100 doses and reconstituted by 100 ml of cool and sterile saline water; 10<sup>3.5</sup> TCID<sub>50</sub>

200 was administered per animal as recommended by the manufacturer. A suspension of 1 ml  
201 vaccine was injected subcutaneously at the neck side (NVI, 2010 ).

202

#### 203 2.3.4. Data management and analysis

204 Descriptive statistics were used to describe the morbidity and mortality in cattle populations  
205 with different vaccination coverage.

206 To analyse the association between the occurrence of LSD infections in animals (i.e. the  
207 cases, which are assumed to be binomial distributed) and independent variables (vaccination  
208 status, breed, age, sex, herdtype, and location), multivariable logistic regression was performed  
209 (STATA version 14). Vaccination status was the main effect of interest while location, breed,  
210 age, sex and herdtype were added as additional explanatory variables. All factors were fitted in  
211 a multivariable regression model and the final model was obtained by a backward stepwise  
212 elimination procedure while checking for confounding. For that purpose confounding was  
213 defined as a change of at least 25% in any of the regression coefficients after removing a non-  
214 significant ( $p > 0.05$ ) variable from the model. Interactions were tested for all combinations of  
215 the significant main effects. Generalised estimating equations (GEE, population averaged  
216 model) was run using herd as random effect. An exchangeable correlation structure was  
217 specified for the random effect and results were expressed as Odds ratio (OR) and its 95%  
218 confidence interval (CI).

219 To estimate the effect of vaccination on the severity (mild, moderate or severe) of LSD,  
220 first a univariable and then multivariable (backwards elimination process) ordered logistic  
221 regression analysis was run by incorporating breed, age, sex, herdtype, and kebele as potential  
222 factor and retaining it in the model as confounder when necessary. The probability of a  
223 vaccinated or unvaccinated infected animal falling in either of the severity categories was  
224 computed using estimated coefficients and the associated cut points of the ordered logistic

225 regression analysis. Proportionality of odds across response categories was tested using the  
226 approximate likelihood-ratio test (omodel logit command in STATA version 14).

227         Multivariable regression analysis using a generalized linear model (GLM) was  
228 performed to assess the effect of vaccination on the transmission of LSD by setting LSD  
229 infection of animals as binomial (yes/no) dependent variable and vaccination status (yes/no)  
230 and fraction of vaccinated among the infected (FracVaccI) as independent variables. The model  
231 was fit using the complementary loglog (cloglog) link function and log (number of infected  
232 animals/total number of animals per sub-kebele) as offset (Velthuis et al., 2003) using STATA  
233 version 14. The susceptibility and infectiousness coefficients obtained from the analysis were  
234 used to calculate the transmission parameters by inserting them into the formulae described in  
235 Table 1. Note that in this case we observed the total outbreak in the sub-kebele and thus the  
236 regression coefficient estimates pertain to the final size of the outbreak and thus we directly  
237 estimate the reproduction ratio R rather than the transmission rate parameter  $\beta$ .

238         Vaccine efficacy for susceptibility (VEs) and infectiousness (VEi) were estimated using  
239 formula 1 and 2 as described by Halloran et al. (2010) and Aznar et al. (2011) and for this the  
240 four transmission parameters with their expression were defined (Table 1).

$$241 \quad VEs = 1 - \left( \frac{Ruv}{Ruu} \right) = 1 - \left( \frac{Rvv}{Rvu} \right) \quad (1)$$

$$242 \quad VEi = 1 - \left( \frac{Rvu}{Ruu} \right) = 1 - \left( \frac{Rvv}{Ruv} \right) \quad (2)$$

243         A vaccine with an efficacy of 0 was considered as not effective whereas a value of 1  
244 was considered fully efficacious. Values of vaccine efficacies above 0.7 are considered ‘good’,  
245 whereas vaccine efficacies in the range of 0.3 to 0.7 are generally considered ‘reasonable’  
246 (Halloran et al., 2010; Lu. et al., 2013). However, this interpretation of vaccine efficacy does  
247 not correspond to whether vaccination will reduce R so that  $R < 1$ , because whether  $R < 1$  also  
248 depends on the R in the absence of vaccination.

249 The reproduction ratio in vaccinated animals was calculated by multiplying the effects  
250 of vaccination on susceptibility ( $\exp(\text{coefficient of the independent variable Vaccination})$ ), and  
251 on infectiousness ( $\exp(\text{coefficient of the fraction of vaccinated among the infected})$ ) and the  
252 intercept of the regression model. Whereas R for unvaccinated was calculated from the  
253 exponent of the intercept only.

254

### 255 **3. Results**

#### 256 **3.1. Questionnaire survey**

257 Based on the herd owner's response, the vaccination coverage at herd level was estimated to be  
258 56.3%. The public veterinary service vaccinated the majority (88.9%) of the herds and more  
259 than 95% of the herds did not get routine prophylactic vaccination against LSD but were  
260 vaccinated just after the LSD index case was reported in a neighbouring kebele. More than 60%  
261 of the herd owners deemed the vaccine to be of low to very low efficacy in protecting against  
262 clinical LSD, however, almost all of them responded that the vaccine did not induce any adverse  
263 reaction after vaccination (Table 2).

264

#### 265 **3.2. Follow-up study**

##### 266 3.2.1. Description of LSD occurrence and vaccination

267 The follow-up study was undertaken in 10 sub-kebeles with 339 infected herds comprising a  
268 total of 2053 cattle of which 1304 (63.5%) were vaccinated (Table 3). Herd size varied from 1  
269 (n=6) to 37 (n=1) with an average of 6 and a median of 6 animals. About 95% of the herds had  
270 10 or less animals. The study population consisted of 346 (16.8%) calves, 263 (12.8%) heifers,  
271 227 (11.1%) bulls, 490 (23.9%) cows and 727 (35.4%) oxen. Of the 2053 animals, 526 (25.6%)  
272 were diagnosed with LSD, 233 (31.1%) in the unvaccinated group and 293 (22.5%) in the

273 vaccinated group (Chi-square test:  $p < 0.001$ ). The PCR results confirmed the LSD infection in  
274 all ten sub-kebeles.

275 The multivariable population averaged model showed that herd did not contribute  
276 significantly to the total variance. Therefore multivariable logistic regression without random  
277 effects was performed which showed that the estimates and their significance were very similar  
278 to the random effects model. All variables remained significant in the multivariable analysis  
279 except herdtype but this variable confounded the estimates of location. Results show that  
280 vaccination significantly decreased the risk of LSD (OR= 0.49, 95% CI: 0.37; 0.64).  
281 Crossbreeds, males and older age were associated with increased risk to be LSD positive  
282 compared to their references and the interaction between vaccination and breed was significant.  
283 Vaccination is more efficient in crossbreed (OR=  $0.49 * 0.43 = 0.21$ ) than local breed (OR=0.49)  
284 animals (Table 4).

285

### 286 3.2.2. LSD severity and vaccination

287 The severity of LSD was assessed on a total of 480 clinically infected cattle (264 vaccinated  
288 and 216 unvaccinated). In unvaccinated animals, the majority of the affected animals (50.5%)  
289 were categorized as severe and 9.7% fell in the mild category whereas in vaccinated animals  
290 these figures were 42.8% and 17.1% respectively (Table 5). The results of the multivariable  
291 ordered logistic model showed that only vaccination was significantly associated with a  
292 different (lower) severity score (Odds Ratio (OR) = 0.68, 95% confidence interval (CI): 0.49;  
293 0.96). The test for the proportional odds assumption was not significant ( $p = 0.21$ ) indicating  
294 that it is valid to report the OR as 0.68. Furthermore, the predicted fraction showed that the  
295 probability of developing moderate and severe disease was slightly higher in unvaccinated  
296 animals (0.89) compared to vaccinated animals (0.84).

297

### 298 3.2.3. LSD vaccine efficacy with respect to transmission

299 The multivariable GLM analysis showed that both the susceptibility ( $\exp(b) = 0.54$ , 95% CI:  
300 0.44; 0.66) and infectiousness ( $\exp(b) = 1.83$ , 95% CI: 1.28; 2.61) effects of the vaccine are  
301 significant and thus the effects are a reduction in susceptibility by a factor 2 and an increase in  
302 infectiousness by a factor 2 (Table 6).

303 A 0.46 vaccine efficacy for susceptibility and -0.83 for infectiousness recorded in this study  
304 were obtained by inserting the corresponding estimated partial reproduction ratios ( $R_{uu} = 1.21$ ,  
305  $R_{uv} = 0.65$ ,  $R_{vu} = 2.22$  and  $R_{vv} = 1.19$ ) into formula 1 and 2 (Table 1 and 6).

306 The estimated reproduction ratios for vaccinated and unvaccinated cattle were almost equal:  
307 1.19 (95% CI: 1.02-1.39) and 1.21 (95% CI: 1.01-1.46). The 0.98 (95% CI: 0.73-1.33) reduction  
308 in R by vaccination was not significantly different from 1 ( $p = 0.92$ ).

309

## 310 **4. Discussion**

311 LSD vaccine breakdown and a concomitant morbidity are reported in Ethiopian cattle since  
312 1993 (Carn, 1993) while vaccination with KS1 O-180 vaccine is the major control method in  
313 the country. However, the efficacy of KS1 O-180 virus strain vaccine against natural LSD  
314 infections under field conditions and its impact on the transmission and severity of the disease  
315 is largely unknown and both are estimated in this paper.

316

### 317 **4.1. Questionnaire survey**

318 The questionnaire survey shows that in almost all study districts no regular vaccination program  
319 for LSD is applied. This is related to the long time (5 or more years) interval between LSD  
320 epidemics (Woods, 1988) and resource limitation. LSD vaccination is usually initiated by the  
321 appearance of an index case in an area. Therefore, vaccination for LSD is commonly carried  
322 out at the face of the outbreak to control the disease occurrence. However, vaccinating animals



323 during an outbreak may aggravate the transmission of LSD due to iatrogenic transmission from  
324 healthy looking, incubating animals to susceptible animals (Hunter and Wallace, 2001). The  
325 survey also showed that most of the vaccinations were provided by the public veterinary  
326 service. This clears out the suspect that the vaccine failure might be related to the administration  
327 of the vaccine by incompetent practitioners (and that apply LSD vaccination illegally).

328         Vaccination coverage is an important issue in disease control. Cattle populations with  
329 low vaccination coverage are assumed to remain at higher risk for the disease. The 56.3%  
330 vaccination coverage at herd level estimated in this study is low given that the vaccine is  
331 provided free of charge. The reason for low coverage might be related to owner's belief that the  
332 vaccine is not protective. More than 60% of the herd owners interviewed in the questionnaire  
333 survey reported low effectiveness of KS1 O-180 vaccine in protecting cattle against clinical  
334 LSD confirming the estimated poor performance of the vaccine (Ayelet et al., 2013; Gelaye et  
335 al., 2015). However, the low vaccination coverage is not related to vaccine adverse effects as  
336 almost all respondents did not indicate any adverse effect. This is in agreement with what  
337 Gelaye et al. (2015) reported for the vaccine. However, in other countries adverse reactions in  
338 cattle vaccinated with sheep pox and Neethling virus based vaccine have been reported like  
339 swelling on the injection site and developing active LSD (Weiss, 1968; Yeruham et al., 1994;  
340 Ben-Gera et al., 2015; Abutarbush et al., 2016).

#### 341 **4.2. Follow-up study**

342 The 22.5% morbidity in vaccinated animals recorded in the follow-up study is comparable to  
343 23.8% morbidity reported in central Ethiopia in cattle vaccinated with Kenyan sheep pox  
344 vaccine strain (Ayelet et al., 2013). However, a much lower morbidity of 4.7% (Abutarbush,  
345 2014), 11% (Brenner et al., 2009) and 1.6% (Ben-Gera et al., 2015) were recorded in vaccinated  
346 cattle of Jordan and Israel. This difference might be attributed to the difference in the quality

347 of the vaccine used, vaccination coverage, management system, environment or climate  
348 difference of the areas where the animals are kept.

349 The factors age group, breed, sex, herdtype and location were included into the logistic  
350 regression model to adjust the estimate of vaccination. The adjusted odds ratio for vaccination  
351 was 0.49 which indicates that vaccination is protective for LSD. Unvaccinated animals have  
352 2.04 (1/0.49) times higher odds to acquire LSD than vaccinated ones. The interaction between  
353 vaccination and breed was significant and it revealed that vaccination was more efficient in  
354 crossbreed (OR= 0.21) than local breed (OR=0.49) animals. This might be related with the more  
355 susceptibility nature of Holstein-Zebu cross to LSD than pure local Zebu animals (Davies 1991;  
356 OIE, 2010). Possible confounding factors which are not measured in this study include  
357 movement of animals and vector density. No animal movement restriction was applied in the  
358 study area; animals move freely from area to area. This practice was similar in all study kebeles  
359 and for both vaccinated and unvaccinated animals. Vector density is also assumed to be similar  
360 in all study kebeles because they are located in the same geographical area with similar weather  
361 conditions and altitude and on top of that they are all within the range of the insect flight zone.

362 Vaccination was associated with less severe LSD symptoms. This finding is in  
363 agreement with the observation of Abutarbush (2014) who reported a considerable change in  
364 feed intake and milk production, fever, and a longer duration of illness in the majority of  
365 unvaccinated cattle as compared to vaccinated cattle. Hence, LSD vaccination reduces disease  
366 severity and as consequence it may prevent part of the production loss due to LSD. Increased  
367 vaccine dose is claimed to improve the protective efficacy of the vaccine. Ben-Gera et al. (2015)  
368 reported a low incidence (1.85%) in cattle vaccinated with a 10 fold increased dose of RM65  
369 vaccine. The regular vaccine dose used to immunize cattle against LSD in Ethiopia is 10 fold  
370 compared what used to immunize sheep and goat. For cattle, LSD vaccine contains  $10^{3.5}$  TCID<sub>50</sub>  
371 attenuated virus per field dose while for sheep and goat it is,  $10^{2.5}$  TCID<sub>50</sub> per dose (NVI, 2010).

372 The vaccine efficacy of 0.46 as estimated for susceptibility is within the ‘reasonable’  
373 efficacy range of 0.3 to 0.7 (Halloran et al., 2010; Lu et al., 2013). This indicates that vaccination  
374 reduces susceptibility to LSD 2.17 times ( $1/(1-0.54)$ ). However, vaccinated infected animals  
375 are 1.83 times more infectious than unvaccinated infected ones. This is contradictory from what  
376 is expected from a vaccine. The increased infectiousness might be related with disease  
377 management practices. In the usual management practice, diseased animals are isolated and  
378 penned separately from healthy animals. However, the situation in vaccinated LSD affected  
379 animals is different, they are less diseased (not easily noticed) and thus remain longer in the  
380 herd (not isolated or removed) while they are infectious. This condition might be favourable  
381 for the transmission of the virus. Therefore, in this regard, animal disease management might  
382 contribute to increased infectiousness. However, this finding needs further investigation  
383 because the disease management and other factors which can influence the infectiousness were  
384 not under control. In general, the gain in decreasing susceptibility in vaccinated cattle is  
385 cancelled out by almost the same increment of infectiousness and this indicates that KS1 O-180  
386 vaccine is not effective in controlling LSD in cattle populations. The overall low efficacy of the  
387 vaccine substantiates the previous findings that vaccination against LSD does not provide  
388 protection from clinical disease (Ayelet et al., 2013; Abutarbush, 2014; Gari et al., 2015). Most  
389 LSD vaccines currently available, except the homologous Neethling vaccine, provide poor  
390 protection against LSD transmission (Brenner et al., 2009; Somasundaram, 2011; Tuppurainen  
391 et al., 2014; Ben-Gera et al., 2015), which is a challenge for the control of the disease.

392 Although vaccinating cattle against LSD is considered the main control option in  
393 resource poor countries like Ethiopia, little is known about the effect of vaccination on the  
394 disease dynamics. In the current study, the estimated reproduction ratios were 1.21 and 1.19 for  
395 unvaccinated and vaccinated cattle, respectively. In both cases R is greater than 1 and confirms  
396 that LSD virus can spread in cattle populations, regardless of their vaccination status, and can

397 cause a major outbreak. This shows that vaccination with KS1 O-180 vaccine alone cannot  
398 eliminate the disease from a cattle population. Thus, a more competent LSD vaccine and other  
399 additional measures, like movement control, detection and removal of infected animals, are  
400 needed to bring the reproduction ratio to below 1.0.

401 An observational study was chosen for this study because it is less costly and enables to  
402 assess the performance of the vaccine under real-life circumstances, including the complex and  
403 not easily controllable exposure to LSDV due to the insect vectors involved. Important  
404 confounders were measured and equal exposure risk of vaccinated and unvaccinated animals  
405 were assumed. Furthermore, the study design avoids the ethical problem of using a placebo  
406 when an approved vaccine is available (Torvaldsen and McIntyre, 2002).

407 Observational studies are prone to potential biases due to its uncontrolled nature. The  
408 biases may be related to selection, misclassification of cases, confounding factors, dealing with  
409 the impact of unknown or unmeasured factors (Dohoo et al., 2003), missing information, and  
410 non-comparability of groups. The distribution of potentially confounding variables among the  
411 study groups and other variables which were not considered might also be a source of bias.  
412 Another limitation to this study is related to the severity assessment; subjectivity might be  
413 somehow involved in allocating affected animals into different categories and on few occasions  
414 the observer might have been unblinded for the vaccination status of the animal because the  
415 owner might have complained about the poor efficacy of the vaccine. We assumed that  
416 exposure to infection was equal in both vaccinated and unvaccinated animals, that all important  
417 confounders were measured and adjusted for by the model used. Considering these limitations,  
418 the results reported here should be interpreted carefully.

419

## 420 **5. Conclusion**

421 The results of our study showed that KS1 O-180 strain vaccine reduces susceptibility of cattle  
422 to LSD but it also increases infectiousness by about the same amount, partially because animals  
423 with less severe disease signs may remain undetected in the herd for longer periods. Generally,  
424 the vaccine has poor efficacy in protecting cattle populations against LSD, neither by direct  
425 clinical protection nor by reducing transmission. Therefore, the prevailing situation dictates the  
426 urgent need of a competent LSD vaccines development to control LSD in endemic countries  
427 and to halt its current spread to free countries and continents.

428 **Conflicts of interest:** None

429

#### 430 **Acknowledgments**

431 The authors would like to thank Nuffic (Netherlands organization for international cooperation  
432 in higher education) for funding the study. We would like to extend our gratitude to the National  
433 Animal Health Diagnostic and Investigation Centre, Ethiopia for assistance in field work and  
434 laboratory confirmation of the disease. We also thank district animal health professionals and  
435 the herd owners for their kind collaboration in collecting and providing information for the  
436 study.

#### 437 **Reference**

438 Abutarbush, S.M., 2014. Efficacy of vaccination against lumpy skin disease in Jordanian cattle.  
439 Vet. Rec. 175.

440 Abutarbush, S.M., Hananeh, W.M., Ramadan, W., Al Sheyab, O.M., Alnajjar, A.R., Al Zoubi,  
441 I.G., Knowles, N.J., Bachanek-Bankowska, K., Tuppurainen, E.S., 2016. Adverse  
442 reactions to field vaccination against lumpy skin disease in Jordan. *Transbound. Emerg.*  
443 *Dis.* 63, e213-219.

444 APHRD, 2012. Ethiopia animal health yearbook 2011 Animal and Plant Health Regulatory  
445 Directorate (APHRD), Addis Ababa, Ethiopia.

446 Ayelet, G., Abate, Y., Sisay, T., Nigussie, H., Gelaye, E., Jemberie, S., Asmare, K., 2013.  
447 Lumpy skin disease: preliminary vaccine efficacy assessment and overview on outbreak  
448 impact in dairy cattle at Debre Zeit, central Ethiopia. *Antivir. Res.* 98, 261-265.

449 Aznar, I., McGrath, G., Murphy, D., Corner, L.A., Gormley, E., Frankena, K., More, S.J.,  
450 Martin, W., O'Keefe, J., De Jong, M.C., 2011. Trial design to estimate the effect of  
451 vaccination on tuberculosis incidence in badgers. *Vet. Microbiol.* 151, 104-111.

452 Ben-Gera, J., Klement, E., Khinich, E., Stram, Y., Shpigel, N.Y., 2015. Comparison of the  
453 efficacy of Neethling lumpy skin disease virus and x10RM65 sheep-pox live attenuated  
454 vaccines for the prevention of lumpy skin disease - The results of a randomized  
455 controlled field study. *Vaccine* 33, 4837-4842.

456 Brenner, J., Bellaiche, M., Gross, E., Elad, D., Oved, Z., Haimovitz, M., Wasserman, A.,  
457 Friedgut, O., Stram, Y., Bumbarov, V., Yadin, H., 2009. Appearance of skin lesions in  
458 cattle populations vaccinated against lumpy skin disease: statutory challenge. *Vaccine*  
459 27, 1500-1503.

460 Carn, 1993. Control of capripoxvirus infections. *Vaccine* 11, 1275-1279.

461 Dohoo, I., Martin, W., Stryhn, H., 2003. *Veterinary Epidemiologic Research*. AVC Inc.  
462 Charlottetown, Canada. pp. 1-21.

463 Davies, F.G., 1991. Lumpy skin disease, an African capripox virus disease of cattle. *Br. Vet. J*  
464 147, 489-503.

465 De Jong, M.C.M., 1994. Experimental quantification of vaccine induced reduction in virus  
466 transmission reduction. *Vaccine* 12, 761-766.

467 Diekmann, O., Heesterbeek, J.A.P., Metz, J.A.J., 1990. On the definition and the computation  
468 of the basic reproduction ratio  $R_0$  in models for infectious diseases in heterogeneous  
469 populations *J. Math. Biol.* 28, 365-382.

470 Gari, G., Abie, G., Gizaw, D., Wubete, A., Kidane, M., Asgedom, H., Bayissa, B., Ayelet, G.,  
471 Oura, C.A., Roger, F., Tuppurainen, E.S., 2015. Evaluation of the safety,  
472 immunogenicity and efficacy of three capripoxvirus vaccine strains against lumpy skin  
473 disease virus. *Vaccine* 33, 3256-3261.

474 Gari, G., Bonnet, P., Roger, F., Waret-Szkuta, A., 2011. Epidemiological aspects and financial  
475 impact of lumpy skin disease in Ethiopia. *Prev. Vet. Med.* 102, 274-283.

476 Gari, G., Waret-Szkuta, A., Grosbois, V., Jacquiet, P., Roger, F., 2010. Risk factors associated  
477 with observed clinical lumpy skin disease in Ethiopia. *Epidemiol. Infect.* 138, 1657-  
478 1666.

479 Gelaye, E., Belay, A., Ayelet, G., Jenberie, S., Yami, M., Loitsch, A., Tuppurainen, E.,  
480 Grabherr, R., Diallo, A., Lamien, C.E., 2015. Capripox disease in Ethiopia: Genetic  
481 differences between field isolates and vaccine strain, and implications for vaccination  
482 failure. *Antivir. Res.* 119, 28-35.

483 Gelaye, E., Lamien, C.E., Silber, R., Tuppurainen, E.S., Grabherr, R., Diallo, A., 2013.  
484 Development of a cost-effective method for capripoxvirus genotyping using snapback  
485 primer and dsDNA intercalating dye. *PloS One* 8, e75971.

486 Halloran, M.E., Longini, J.I., Struchiner, C.J., 2010. *Design and Analysis of Vaccine Studies.*  
487 Springer, New York. pp. 19-45.

488 Halloran, M.E., Struchiner, C.J., Longini, J.I., 1997. Study designs for evaluating different  
489 efficacy and effectiveness aspects of vaccines. *Am. J. Epidemiol.* 146,789-803.

490 Heffernan, J.M., Smith, R.J., Wahl, L.M., 2005. Perspectives on the basic reproductive ratio. *J.*  
491 *R. Soc. Interface* 2, 281-293.

492 Hunter, P., Wallace, D., 2001. Lumpy skin disease in southern Africa: a review of the disease  
493 and aspects of control. *J. S. Afr. Vet. Ass.* 72, 68-71.

494 Kumar, S.M., 2011. An outbreak of lumpy skin disease in a Holstein dairy herd in Oman: A  
495 clinical report *Asian J. Anim. Vet. Adv.* 6, 851-859.

496 Longini, Jr., I.M., Sagatelian, K., Rida, W.N., Halloran, M.E., 1998. Optimal vaccine trial  
497 design when estimating vaccine efficacy for susceptibility and infectiousness from  
498 multiple populations. *Stat. Med.* 17, 1121-1136.

499 Lu, Z., Schukken, Y.H., Smith, R.L., Mitchell, R.M., Gröhn, Y.T., 2013. Impact of imperfect  
500 *Mycobacterium avium* subsp. *paratuberculosis* vaccines in dairy herds: A mathematical  
501 modeling approach. *Prev. Vet. Med.* 108, 148-158.

502 Mebratu, G.Y., Kassa, B., Fikre, Y., Berhanu, B., 1984. Observation on the outbreak of lumpy  
503 skin disease in Ethiopia *Rev. Elev. Méd. Vét. Pays Trop.* 37, 395-399.

504 NVI, 2010 Product catalogue. User manual for lumpy skin disease vaccine. Issue In: National  
505 Veterinary Institute (Ed.), 12.

506 OIE, 2010. Manual of diagnostic tests and vaccines for terrestrial animals, chapter 2.4.14,  
507 Lumpy skin disease. OIE, Paris.  
508 [http://web.oie.int/eng/normes/MANUAL/A\\_Index.htm](http://web.oie.int/eng/normes/MANUAL/A_Index.htm) (accessed February 26,  
509 2016). OIE, Paris.

510 OIE, 2015. Manual of diagnostic tests and vaccines for terrestrial animals, volume 1, chapter  
511 1.1.6, principles of veterinary vaccine production. OIE, Paris.  
512 [http://www.oie.int/fileadmin/Home/eng/Health\\_standards/tahm/1.01.06\\_VACCINE\\_P](http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/1.01.06_VACCINE_P)  
513 [RODUCTION.pdf](http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/1.01.06_VACCINE_P) (accessed March 8, 2016). OIE, Paris.

514 OIE, 2016. OIE-Listed diseases, infections and infestations in force in 2016. Available at:  
515 <http://www.oie.int/animal-health-in-the-world/oie-listed-diseases-2016/> (accessed  
516 March 8, 2016). OIE, Paris.



517 Quinn, P.J., Carter, M.E., Markey, B., Carter, G.R., 1999. *Clinical Veterinary Microbiology*.  
518 Elsevier Ltd, London. pp. 486-495.

519 Quinn, P.J., Markey, B.K., Carter, M.E., Donnelly, W.J., Leonard, F.C., 2002. *Veterinary*  
520 *Microbiology and Microbial Disease*. Blackwell Science, Great Britain. pp. 335-342.

521 Radostits, O.M., Gay, C.C., Hinchcliff, K.W., Constable, P.D., 2007. *Veterinary Medicine: A*  
522 *Textbook of the Diseases of Cattle, Sheep, Pigs, Goats and Horses*. Sounders Elsevier,  
523 Spain. pp. 1424-1426.

524 Smith, P.G., Rodrigues, L.C., Fine, P.E., 1984. Assessment of the protective efficacy of  
525 vaccines against common diseases using case-control and cohort studies. *Int. J.*  
526 *Epidemiol.* 13, 87-93.

527 Somasundaram, M.K., 2011. An outbreak of lumpy skin disease in a Holstein dairy herd in  
528 Oman: a clinical report. *Asian J. Anim. Vet. Adv.* 6, 851-859.

529 Tasioudi, K.E., Antoniou, S.E., Iliadou, P., Sachpatzidis, A., Plevraki, E., Agianniotaki, E.I.,  
530 Fouki, C., Mangana-Vougiouka, O., Chondrokouki, E., Dile, C., 2016. Emergence of  
531 lumpy skin disease in Greece, 2015. *Transbound. Emerg. Dis.* 63, 260-265.

532 Torvaldsen, S., McIntyre, P.B., 2002. Observational methods in epidemiologic assessment of  
533 vaccine effectiveness. *Commun. Dis. Intell. Q. Rep.* 26, 451-457.

534 Tuppurainen, E.S., Oura, C.A., 2012. Review: lumpy skin disease: an emerging threat to  
535 Europe, the Middle East and Asia. *Transbound. Emerg. Dis.* 59, 40-48.

536 Tuppurainen, E.S., Pearson, C.R., Bachanek-Bankowska, K., Knowles, N.J., Amareen, S.,  
537 Frost, L., Henstock, M.R., Lamien, C.E., Diallo, A., Mertens, P.P., 2014.  
538 Characterization of sheep pox virus vaccine for cattle against lumpy skin disease virus.  
539 *Antivir. Res.* 109, 1-6.

540 Tuppurainen, E.S., Venter, E.H., Shisler, J.L., Gari, G., Mekonnen, G.A., Juleff, N., Lyons,  
541 N.A., De Clercq, K., Upton, C., Bowden, T.R., Babiuk, S., Babiuk, L.A., 2017.

542 Review: capripoxvirus diseases: current status and opportunities for control.  
543 *Transbound. Emerg. Dis.* 64, 729-745.

544 Tuppurainen, E.S.M., Venter, E.H., Coetzer, J.A.W., 2005. The detection of lumpy skin disease  
545 virus in samples of experimentally infected cattle using different diagnostic techniques.  
546 *Onderstepoort J. Vet. Res.* 72, 153-164.

547 Van der Goot, J.A., Van Boven, M., Koch, G., de Jong, M.C.M., 2007. Variable effect of  
548 vaccination against highly pathogenic avian influenza (H7N7) virus on disease and  
549 transmission in pheasants and teals. *Vaccine* 25, 8318-8325.

550 Velthuis, A.G.J., De Jong, M.C.M., Kamp, E.M., Stockhofe, N., Verheijden, J.H.M., 2003.  
551 Design and analysis of an *Actinobacillus pleuropneumoniae* transmission experiment.  
552 *Prev. Vet. Med.* 60, 53-68.

553 WAHID, 2016. Summary of Immediate notifications and Follow-ups. World Animal Health  
554 Information Database (WAHID).

555 Weiss, K.E., 1968. Lumpy skin disease virus. *Virol. Monogr.* 3, 111-131.

556 Woods, J.A., 1988. Lumpy skin disease- A review. *Trop. Anim. Hlth Prod.* 20, 11-17.

557 Yeruham, I., Perl, S., Nyska, A., Abraham, A., Davidson, M., Haymovitch, M., Zamir, O.,  
558 Grinstein, H., 1994. Adverse reactions in cattle to a capripox vaccine. *Vet. Rec.* 135,  
559 330-332.

560

561

562

563

564

565

566

567

568 Table 1. The fitted model to estimate LSD transmission rates in cattle populations with  
569 different levels of vaccination coverage in Mota town and Hulet Ejju Enessie district of  
570 Ethiopia.

571

Partial R value	Description	Expression <sup>b</sup>
<i>R<sub>uu</sub></i>	Transmission from an unvaccinated to an unvaccinated animal	$e^{c_0}$
<i>R<sub>uv</sub></i>	Transmission from an unvaccinated to a vaccinated animal	$e^{c_0 + c_1}$
<i>R<sub>vu</sub></i>	Transmission from a vaccinated to an unvaccinated animal	$e^{c_0 + c_2}$
<i>R<sub>vv</sub></i>	Transmission from a vaccinated to a vaccinated animal	$e^{c_0 + c_1 + c_2}$

572 <sup>a</sup> Fraction of vaccinated among the infected.

573 <sup>b</sup> Relation between infection parameters and estimated coefficients of the model, where  $c_0$  is the estimated intercept and  $c_1$  and  
574  $c_2$  are the estimated regression coefficients of the variables vaccination and fracVaccI respectively.

575 Table 2. Ethiopian herd owners' opinion on LSD vaccine effectiveness and adverse reactions.

576

Level	Vaccine effectiveness			Vaccine adverse reactions		
	Frequency	Percent	Cum. percent	Frequency	Percent	Cum. percent
Very high	0	0	0	1	0.8	0.8
High	29	23.2	23.2	1	0.8	1.6
Moderate	20	16.0	39.2	0	0	1.6
Low	6	4.8	44	0	0	1.6
Very low	70	56.0	100	123	98.4	100
<b>Total</b>	<b>125</b>	<b>100</b>	<b>100</b>	<b>125</b>	<b>100</b>	<b>100</b>

577

578 Table 3. LSD infection and death proportion in vaccinated and unvaccinated cattle population at different localities of Mota town and Hulet Ejj  
 579 Enessie district of Ethiopia.

580

Sub-kebele/town	Total	Population		Total	Unvaccinated		Total	Vaccinated	
		No. (Proportion) infected	No. (Proportion) died		No. (Proportion) infected	No. (Proportion) died		No. (Proportion) infected	No. (Proportion) died
Mota	169	40 (0.237)	2 (0.012)	87	26 (0.299)	2 (0.023)	82	14 (0.171)	0 (0.000)
Akobe	108	22 (0.204)	0 (0.000)	74	14 (0.189)	0 (0.000)	34	8 (0.235)	0 (0.000)
Atetanat	134	50 (0.373)	8 (0.060)	51	19 (0.373)	2 (0.039)	83	31 (0.373)	6 (0.072)
Kesmender	145	35 (0.241)	2 (0.014)	38	9 (0.237)	0 (0.000)	107	26 (0.243)	2 (0.019)
Komma	76	16 (0.211)	0 (0.000)	7	3 (0.429)	0 (0.000)	69	13 (0.188)	0 (0.000)
Semo	220	54 (0.245)	0 (0.000)	214	53 (0.248)	0 (0.000)	6	1 (0.167)	0 (0.000)
Shewaber	187	44 (0.235)	2 (0.011)	108	28 (0.259)	1 (0.009)	79	16 (0.203)	1 (0.013)
Webmariam	432	109 (0.252)	8 (0.019)	127	64 (0.504)	4 (0.031)	305	45 (0.148)	4 (0.013)
Yerez	430	125 (0.291)	7 (0.016)	23	10 (0.435)	2 (0.087)	407	115 (0.283)	5 (0.012)
Zenabach	152	31 (0.204)	0 (0.000)	20	7 (0.350)	0 (0.000)	132	24 (0.182)	0 (0.000)
<b>Overall</b>	<b>2053</b>	<b>526 (0.256)</b>	<b>29 (0.014)</b>	<b>749</b>	<b>233 (0.311)</b>	<b>11 (0.015)</b>	<b>1304</b>	<b>293 (0.225)</b>	<b>18 (0.014)</b>

581

582

583 Table 4. Multivariable analysis of potential riskfactors for LSD infection in Mota town and

584 Hulet Ejju Enessie district of Ethiopia (n=2053) using logistic regression.

585

<b>Risk factor</b>	<b>Category</b>	<b>No. of animals</b>	<b>No. LSD</b>	<b>Odds Ratio</b>	<b>95% CI</b>	<b>p-value</b>
Vaccination	Vaccinated	1304	293	0.49	0.37-0.64	0.000
	Unvaccinated	749	233	Ref		
Breed	Cross	312	95	3.83	2.25-6.53	0.000
	Local	1741	431	Ref		
Age group	Calf	346	46	Ref		
	Young	490	91	1.50	1.01-2.22	0.043
	Adult	1217	389	3.02	2.14-4.25	0.000
Sex	Male	1120	339	1.79	1.44-2.23	0.000
	Female	933	187	Ref		
Herdtype	Specialized	126	28	0.53	0.22-1.27	0.157
	Mixed	1927	498	Ref		
Location	Ayen Berhan	432	109	1.25	0.60-2.60	0.557
	Beza Bizuhan	564	175	2.12	1.02-4.00	0.044
	Debre Gubae	373	82	1.33	0.63-2.81	0.458
	Hibre Selam	515	120	0.80	0.38-1.66	0.545
	Mota town	169	40	Ref		
Interaction	Vaccinated * cross breed			0.43	0.23-0.81	0.008

586

587 Table 5. LSD severity in vaccinated and unvaccinated cattle population (n= 480) of Ethiopia.

588

<b>Severity level</b>	<b>Vaccinated</b>		<b>Unvaccinated</b>	
	<b>Number</b>	<b>Proportion in %</b>	<b>Number</b>	<b>Proportion in %</b>
Mild	45	17.1	21	9.7
Moderate	106	40.2	86	39.8
Severe	113	42.8	109	50.5
<b>Total</b>	<b>264</b>	<b>100</b>	<b>216</b>	<b>100</b>

589

590

591 Table 6. Analysis of the effect of vaccination on susceptibility and infectiousness of LSD in  
 592 Mota town and Hulet Ejju Enessie district of Ethiopia (n=2053) using GLM.

593

<b>Variable</b>	<b>Susceptibility/ infectiousness</b>	<b>Coefficient (b)</b>	<b>Effect (exp(b))</b>	<b>95% CI</b>	<b>p-value</b>
Vaccination	Susceptibility	-0.62	0.54	0.44; 0.66	0.000
FracVaccI <sup>a</sup>	Infectiousness	0.60	1.83	1.28; 2.61	0.001
Constant		0.19	1.21	1.00; 1.46	0.045

594 <sup>a</sup>Fraction of vaccinated among the infected in each population (= sub-kebele).

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612


613

614



615

616



617

618 Figure 1. Map of Ethiopia showing the area where the questionnaire survey was performed.

619

620

621

622

623

624

625

626

627


628

629

630

631

632



633

634 Figure 2. Map of Hulet Ejju Enessie district (Ethiopia) showing LSD vaccine efficacy  
635 observational study site.

636